GUCY2C-targeted cancer immunotherapy: past, present and future

Snook, Adam E.; Magee, Michael S.

doi:10.1007/s12026-011-8253-7

Cited by 11 publications

(4 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To analyze whether plasma-induced ICD could stimulate an adaptive anti-tumor response, we treated subcutaneous CT26 tumors expressing the colorectal cancer antigen GUCY2C 42,43 (CT26-GUCY2C) in Balb/c mice. Mice were treated with either plasma alone or with plasma in combination with the Ad5-GUCY2C-S1 vaccine.…”

Section: Plasma Amplifies Specific T-cell Responses Against Ct26-gucy2c Tumorsmentioning

confidence: 99%

Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors

et al. 2018

Self Cite

View full text Add to dashboard Cite

Immunogenic cell death is characterized by the emission of danger signals that facilitate activation of an adaptive immune response against dead-cell antigens. In the case of cancer therapy, tumor cells undergoing immunogenic death promote cancer-specific immunity. Identification, characterization, and optimization of stimuli that induce immunogenic cancer cell death has tremendous potential to improve the outcomes of cancer therapy. In this study, we show that non-thermal, atmospheric pressure plasma can be operated to induce immunogenic cell death in an animal model of colorectal cancer. , plasma treatment of CT26 colorectal cancer cells induced the release of classic danger signals. Treated cells were used to create a whole-cell vaccine which elicited protective immunity in the CT26 tumor mouse model. Moreover, plasma treatment of subcutaneous tumors elicited emission of danger signals and recruitment of antigen presenting cells into tumors. An increase in T cell responses targeting the colorectal cancer-specific antigen guanylyl cyclase C (GUCY2C) were also observed. This study provides the first evidence that non-thermal plasma is a inducer of immunogenic cell death and highlights its potential for clinical translation for cancer immunotherapy.

show abstract

Section: Plasma Amplifies Specific T-cell Responses Against Ct26-gucy2c Tumorsmentioning

confidence: 99%

Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Second-generation B7H6 CAR T cells can reduce the tumor burden in mice with ovarian cancer.2015 63 ARP2/3+++−NoTumor cells of patients with gastric cancer are positive for Arp2/3, which induces the prompt invasion and metastasis of gastric carcinoma cells.2012 104 Neuropilin-1+++NoNRP-1 expression in gastric cancer tissues is higher than that in normal gastric mucosa and correlates with tumor differentiation and pathological type.2016 65 DSC2+++NoGastric cancers are positive for DSC2, which is frequently expressed in GC.2010 66 AE1+++−NoGastric carcinoma is positive for AE1, but normal gastric tissue is negative. AE1 expression is significantly associated with the development of gastric cancer.2009 67 Colorectal cancerGUCY2C+++−YesSecond-generation GUCY2C CAR-T cells can effectively inhibit the development of colon tumors and can prolong survival.2011 73 AXIN2+−NoAXIN2 and HNKD can be expressed only in human colon cancer-derived cell lines.2001 74 HNKD++++−No CDH17+++++NoCDH17, a member of the cadherin superfamily, is a membrane-associated glycoprotein.2014 75 CK7…”

Section: Application Of Car-t Therapy In Patients With Gastrointestinmentioning

confidence: 99%

CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside

Zhang

Peng

et al. 2016

OncoImmunology

View full text Add to dashboard Cite

The chimeric antigen receptor (CAR) is a genetically engineered receptor that combines a scFv domain, which specifically recognizes the tumor-specific antigen, with T cell activation domains. CAR-T cell therapies have demonstrated tremendous efficacy against hematologic malignancies in many clinical trials. Recent studies have extended these efforts to the treatment of solid tumors. However, the outcomes of CAR-T cell therapy for solid tumors are not as remarkable as the outcomes have been for hematologic malignancies. A series of hurdles has arisen with respect to CAR-T cell-based immunotherapy, which needs to be overcome to target solid tumors. The major challenge for CAR-T cell therapy in solid tumors is the selection of the appropriate specific antigen to demarcate the tumor from normal tissue. In this review, we discuss the application of CAR-T cells to gastrointestinal and hepatic carcinomas in preclinical and clinical research. Furthermore, we analyze the usefulness of several specific markers in the study of gastrointestinal tumors and hepatic carcinoma.

show abstract

“…The identification of a suitable tumor-specific antigen is one of the most important steps in developing immunotherapeutic treatments. Till date four different markers, Carcinoembryonic antigen (CEA), MUC1, Guanylyl cyclase C 26,27,28 , KRAS 29,30 and Tp 5331 , have been studied extensively with wide applications which have been explained later.…”

Section: Selection Criteria For Virotherapymentioning

confidence: 99%

Application of Oncolytic Viruses for Cure of Colorectal Cancer

Davis¹

2015

CRJ

View full text Add to dashboard Cite

Abstract:Colorectal cancer is one of the most commonly diagnosed and lethal cancers worldwide. It is the resultant of multistep processes caused by the accumulation of genetic/epigenetic aberrations. The different therapeutic strategies like radiotherapy, chemotherapy and surgery, used individually or in different combinations, do not remove tumors or their progression all the time. Besides, these procedures involve surrounding cells and tissues. In case of surgery, which is possible only before metastasis, even a single cancer cell left out during surgery, cause further cancer. Focus has been laid in developing agents that could specifically target the cancer cells and leave out the remaining normal cells. This also attempt at total recovery. This was how the focus was laid on viral agents. Over the last two decades, due to various advancements in molecular biology, virotherapy has seen various developments. A special class of viruses called oncolytic viruses have been used as a therapeutic strategy against cancer. These agents have various inherent and engineered factors like enhanced tissue tropism, thereby providing high selectivity; armed with transgenes to deliver therapeutic genes and to perform tumor selective replication, all these factors proving them improved and evolved mechanisms, when compared with other cancer therapeutics. These oncolytic viruses provide greater protection in association with herbal remedies. The purpose of this paper is to provide a detailed account of some of the current observations, developments and insights made in the field of oncolytic virotherapy for targeting colorectal cancer cells. A panel of five oncolytic viruses i.e. adenovirus, herpes virus, reovirus, vaccinia virus and new castle disease virus that are under clinical studies for targeting colorectal cancer cells have been discussed.

show abstract

GUCY2C-targeted cancer immunotherapy: past, present and future

Cited by 11 publications

References 95 publications

Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors

Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors

CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside

Application of Oncolytic Viruses for Cure of Colorectal Cancer

Contact Info

Product

Resources

About